Cargando…
Pulmonary hypertension in lymphangioleiomyomatosis: prevalence, severity and the role of carbon monoxide diffusion capacity as a screening method
BACKGROUND: Lymphangioleiomyomatosis (LAM) is included within group 5 of the current PH classification (unclear multifactorial mechanisms). However, data regarding the occurrence of PH in LAM are scarce. The aims of the study were to describe the prevalence and characteristics of PH in a large cohor...
Autores principales: | Freitas, Carolina S. G., Baldi, Bruno G., Jardim, Carlos, Araujo, Mariana S., Sobral, Juliana Barbosa, Heiden, Gláucia I., Kairalla, Ronaldo A., Souza, Rogério, Carvalho, Carlos R. R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5399314/ https://www.ncbi.nlm.nih.gov/pubmed/28427470 http://dx.doi.org/10.1186/s13023-017-0626-0 |
Ejemplares similares
-
Use of sirolimus in the treatment of lymphangioleiomyomatosis: favorable responses in patients with different extrapulmonary manifestations
por: Freitas, Carolina Salim Gonçalves, et al.
Publicado: (2015) -
Association between pulmonary artery to aorta diameter ratio with pulmonary hypertension and outcomes in diffuse cystic lung diseases
por: Baldi, Bruno Guedes, et al.
Publicado: (2021) -
Doxycycline use in patients with lymphangioleiomyomatosis:
biomarkers and pulmonary function response ,
por: Pimenta, Suzana Pinheiro, et al.
Publicado: (2013) -
Immunohistological features related to functional impairment in lymphangioleiomyomatosis
por: Nascimento, Ellen Caroline Toledo do, et al.
Publicado: (2018) -
Treatment of lymphangioleiomyomatosis and Camões
por: Rufino, Rogério
Publicado: (2015)